BR112013003169A2 - composições e métodos para inibir célula-tronco e células progenitora que se ligam a tecido de linfóide e para regeneração de centros germinativos em tecido linfáticos. - Google Patents

composições e métodos para inibir célula-tronco e células progenitora que se ligam a tecido de linfóide e para regeneração de centros germinativos em tecido linfáticos.

Info

Publication number
BR112013003169A2
BR112013003169A2 BR112013003169A BR112013003169A BR112013003169A2 BR 112013003169 A2 BR112013003169 A2 BR 112013003169A2 BR 112013003169 A BR112013003169 A BR 112013003169A BR 112013003169 A BR112013003169 A BR 112013003169A BR 112013003169 A2 BR112013003169 A2 BR 112013003169A2
Authority
BR
Brazil
Prior art keywords
tissue
regeneration
bind
compositions
methods
Prior art date
Application number
BR112013003169A
Other languages
English (en)
Other versions
BR112013003169B1 (pt
Inventor
Thereza Deisher
Original Assignee
Theresa Deisher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theresa Deisher filed Critical Theresa Deisher
Publication of BR112013003169A2 publication Critical patent/BR112013003169A2/pt
Publication of BR112013003169B1 publication Critical patent/BR112013003169B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)

Abstract

produtos compósitos e método de fabricação. trata-se de um produto e um método de fabricação do produto compósito. o produto compósito inclui (a) um aglutinante de material polimérico e um material que comporta metal ou (b) o aglutinante de material polimérico e um material que comporta carbono. o método inclui aquecer e misturar os componentes do produto compósito e posteriormente formar a mistura aquecida em um formato de produto final, com a etapa de aquecimento sendosuficiente para fundir pelo menos uma parte do aglutinante de material polimérico para facilitar a formação do produto.
BR112013003169-7A 2010-08-18 2011-08-18 Uso de um agente terapêutico que inibe a ligação de células-tronco a tecido linfóide BR112013003169B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US37494310P 2010-08-18 2010-08-18
US61/374,943 2010-08-18
US201161441485P 2011-02-10 2011-02-10
US61/441,485 2011-02-10
US201161449372P 2011-03-04 2011-03-04
US61/449,372 2011-03-04
PCT/US2011/048297 WO2012024519A2 (en) 2010-08-18 2011-08-18 Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues

Publications (2)

Publication Number Publication Date
BR112013003169A2 true BR112013003169A2 (pt) 2016-06-28
BR112013003169B1 BR112013003169B1 (pt) 2022-05-24

Family

ID=45594254

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013003169-7A BR112013003169B1 (pt) 2010-08-18 2011-08-18 Uso de um agente terapêutico que inibe a ligação de células-tronco a tecido linfóide

Country Status (19)

Country Link
US (2) US20120045435A1 (pt)
EP (2) EP3530274A1 (pt)
JP (3) JP6096116B2 (pt)
KR (3) KR101833204B1 (pt)
CN (1) CN103167870B (pt)
AU (1) AU2011291651B2 (pt)
BR (1) BR112013003169B1 (pt)
CA (1) CA2844109C (pt)
CR (1) CR20130117A (pt)
DO (1) DOP2013000043A (pt)
ES (1) ES2738115T3 (pt)
IL (1) IL224727B (pt)
MX (1) MX368272B (pt)
MY (1) MY179491A (pt)
NZ (1) NZ607906A (pt)
RU (1) RU2645069C2 (pt)
SG (2) SG187840A1 (pt)
WO (1) WO2012024519A2 (pt)
ZA (2) ZA201301800B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426740B1 (en) * 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
US11242399B2 (en) 2013-02-19 2022-02-08 Adienne S.A. Anti-CD26 antibodies
EP2767549A1 (en) * 2013-02-19 2014-08-20 Adienne S.A. Anti-CD26 antibodies and uses thereof
WO2016022656A1 (en) * 2014-08-05 2016-02-11 Wayne State University Compositions and methods for treatment of sickle cell disease
EP3355914B1 (en) 2015-09-29 2024-03-06 The General Hospital Corporation A composition comprising bcg for reducing cholesterol.
WO2017083440A1 (en) * 2015-11-09 2017-05-18 The General Hospital Corporation D.B.A Massachusetts General Hospital Unit dose formulations for use as an anti-fugetactic agent
CN107034272B (zh) * 2016-12-14 2020-09-29 河北医科大学第四医院（河北省肿瘤医院） Cxcl2在制备诊断或治疗肺腺癌工具中的应用
CN110475571B (zh) * 2017-04-01 2023-04-04 Avm生物技术有限责任公司 细胞免疫疗法前细胞毒性预调理的替代
WO2018230713A1 (ja) * 2017-06-16 2018-12-20 学校法人同志社 カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
CA3067332A1 (en) 2017-06-16 2018-12-20 The Doshisha Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
JP7458975B2 (ja) * 2017-11-29 2024-04-01 マジェンタ セラピューティクス インコーポレイテッド Ｃｄ５＋細胞の枯渇のための組成物および方法
RU2707281C1 (ru) * 2018-09-17 2019-11-26 Гордейчук Владимир Евгеньевич Способ иммунотерапии раковых заболеваний
EP3488851A1 (en) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
SG11202104084WA (en) * 2018-10-30 2021-05-28 Magenta Therapeutics Inc Methods for allogeneic hematopoietic stem cell transplantation
CN111918645A (zh) 2018-11-14 2020-11-10 Avm生物技术有限责任公司 稳定的糖皮质激素制剂
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
WO2021211450A1 (en) * 2020-04-13 2021-10-21 Fred Hutchinson Cancer Research Center Conditioning regimens for in vivo gene therapy
US20210353685A1 (en) * 2020-05-14 2021-11-18 Brain Cancer Research Institute Augmentation of Cell Therapy Efficacy by Inhibition of Complement Activation Pathways
KR102285160B1 (ko) * 2020-12-24 2021-08-03 주식회사 타임바이오 전구세포에서 유래한 다기능성 엑소좀을 포함하는 피부염 예방 또는 치료용 약학적 조성물
CN116549629A (zh) * 2022-01-30 2023-08-08 江苏众红生物工程创药研究院有限公司 Cd45作为生物标志物在筛查cd26抗体或其衍生物治疗肿瘤有效性和精准性中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837539A (en) 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
GB9323199D0 (en) * 1993-11-10 1994-01-05 Falkenberg J H F Leukaemia treatment
US7862810B2 (en) 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
AU2002310046A1 (en) * 2001-05-22 2002-12-03 Duke University Compositions and methods for inhibiting metastasis
IL146970A0 (en) * 2001-12-06 2002-08-14 Yeda Res & Dev Migration of haematopoietic stem cells and progenitor cells to the liver
CN103393681B (zh) * 2002-05-17 2017-04-12 细胞基因公司 用于治疗和控制多发性骨髓瘤的方法及组合物
US7470538B2 (en) 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
US20040247574A1 (en) * 2003-05-27 2004-12-09 Christopherson Kent W. Methods for enhancing stem cell engraftment during transplantation
US7875273B2 (en) * 2004-12-23 2011-01-25 Ethicon, Incorporated Treatment of Parkinson's disease and related disorders using postpartum derived cells
US20080138415A1 (en) * 2006-09-26 2008-06-12 Mehboob Hussain Composition and method for producing composition for constructing tissue, and tissue construct
EP2086332B1 (en) 2006-11-03 2018-01-10 Multiple Sclerosis Research Center Of New York Bone marrow-derived mesenchymal stem cells as a source of neural progenitors
US20100247491A1 (en) * 2007-02-01 2010-09-30 Christof Westenfelder Potentiation of Stem Cell Homing and Treatment of Organ Dysfunction or Organ Failure
WO2008114876A1 (en) * 2007-03-14 2008-09-25 The University Of Tokyo A method of treating malignant mesothelioma
JP4743215B2 (ja) 2008-02-07 2011-08-10 株式会社ジェイ・エム・エス 血液透析装置
US20090299269A1 (en) 2008-05-29 2009-12-03 John Foley Vascular stimulation to aid intravascular cell replacement therapy
US20100010087A1 (en) 2008-07-10 2010-01-14 Hong John J Methods for Inducing Stem Cell Migration and Specialization with EC-18

Also Published As

Publication number Publication date
EP3530274A1 (en) 2019-08-28
ZA201301800B (en) 2014-07-30
JP2014501694A (ja) 2014-01-23
JP2017081948A (ja) 2017-05-18
IL224727B (en) 2018-02-28
WO2012024519A2 (en) 2012-02-23
KR20140027901A (ko) 2014-03-07
RU2645069C2 (ru) 2018-02-15
RU2013110492A (ru) 2014-09-27
KR102173938B1 (ko) 2020-11-04
JP6437988B2 (ja) 2018-12-12
CN103167870A (zh) 2013-06-19
JP6096116B2 (ja) 2017-03-15
US20120045435A1 (en) 2012-02-23
EP2605765A2 (en) 2013-06-26
ES2738115T3 (es) 2020-01-20
NZ607906A (en) 2015-11-27
US9962408B2 (en) 2018-05-08
MX2013001835A (es) 2013-02-26
US20170128493A1 (en) 2017-05-11
JP6716668B2 (ja) 2020-07-01
CR20130117A (es) 2013-05-31
SG10201600621VA (en) 2016-02-26
CN103167870B (zh) 2018-11-16
MX368272B (es) 2019-09-26
SG187840A1 (en) 2013-03-28
AU2011291651A1 (en) 2013-03-21
DOP2013000043A (es) 2013-09-30
CA2844109A1 (en) 2012-02-23
JP2019059744A (ja) 2019-04-18
WO2012024519A3 (en) 2012-04-19
MY179491A (en) 2020-11-08
KR20180023040A (ko) 2018-03-06
WO2012024519A4 (en) 2012-06-28
AU2011291651B2 (en) 2016-01-14
KR101833204B1 (ko) 2018-03-02
KR20190017065A (ko) 2019-02-19
CA2844109C (en) 2018-11-06
EP2605765B1 (en) 2019-05-08
BR112013003169B1 (pt) 2022-05-24
ZA201402419B (en) 2015-12-23

Similar Documents

Publication Publication Date Title
BR112013003169A2 (pt) composições e métodos para inibir célula-tronco e células progenitora que se ligam a tecido de linfóide e para regeneração de centros germinativos em tecido linfáticos.
BR112013003261A2 (pt) produtos compósitos e método de fabricação.
TR201901059T4 (tr) Bir sertleşme hızlandırıcı kompozisyonun hazırlanması için bir proses
UY36382A (es) Composición combustible sólida formada a partir de desechos sólidos mixtos
MX368186B (es) Aglutinantes y productos asociados.
BR112013010317A2 (pt) produção de biogasolina renovável
MX361924B (es) Un material compuesto y método para preparar el mismo a partir de desperdicios substancialmente sin clasificar.
PH12017500812A1 (en) Process for forming a solid fuel composition from mixed solid waste
WO2012168410A3 (en) Methods for treating lignocellulosic material
MX2018016269A (es) Metodo para la fabricacion aditiva de estructuras inorganicas porosas y compuestos fabricados a partir de estas.
WO2010035005A3 (en) Construction materials
FR2919298B1 (fr) Composition bitume/polymere a reticulation thermoreversible.
IN2013CN03033A (pt)
WO2013191947A3 (en) Renewable fuel composition and method of using the same
BR112013025244A2 (pt) composição de aglutinante aquosa, uso de uma composição de aglutinante aquosa, processo para a produção de um artigo moldado, artigo moldado, uso de um artigo moldado, e, membrana de telhado betumizada
MX337658B (es) Asfalto modificado con caucho pulverizado con estabilidad mejorada.
WO2012015208A3 (en) Silicon carbide and method for manufacturing the same
PH12014501610A1 (en) Production of coal combustion products for use in cementitious materials
PL2137286T3 (pl) Sposób wytwarzania świec
WO2013019328A3 (en) Processes for converting lignocellulosics to reduced acid pyrolysis oil
WO2012015262A3 (en) Silicon carbide and method for manufacturing the same
MY164308A (en) Solid fuel
BR112018004495A2 (pt) briquete de carvão, método para produzir o mesmo, e método para produzir ferro derretido
UA99491C2 (ru) Топливная система, способ ее производства и применения
MY173001A (en) Halogenated polymer composite composition, its manufacturing process and its use

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.21 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/08/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.